The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo.
The aim of this study was to evaluate the anti-cancer effect of a novel organoselenium compound BBSKE (1,2-[bis(1,2-Benzisoselenazolone-3(2H)-ketone)]ethane, BBSKE, PCT: CN02/00412) on cell growth and apoptosis, focusing on the protein activity of Thioredoxin Reductase (TrxR) and Caspase-3, in oral squamous cell carcinoma (OSCC) in vitro and in vivo. Oral squamous cancer cell line Tca8113 was treated with various concentrations of BBSKE. Growth and apoptosis as well as the protein activities were analyzed. Morphologic changes of Tca8113 cells after 24h treatment of BBSKE were determined by fluorescence microscopy. The increase of Caspase-3 activity and decrease of Thioredoxin reductase (TrxR) activity were also measured. BBSKE induced a significant cell growth inhibition and elicited typical apoptotic morphologic changes (chromatic condensation, nucleus fragmentation). This phenomenon was accompanied by a change in protein activity of Thioredoxin reductase (TrxR) and Caspase-3. The anti-cancer effect of BBSKE was then studied in well-established Tca8113 xenografts in nude mice. In those tumors, anti-cancer effects were observed and significantly higher than the controls. Together, these results indicate that BBSKE can inhibit tongue cancer cell proliferation in vitro and in vivo, and induce apoptosis in Tca8113 cell lines partially via inhibiting the activity of TrxR and promoting the activity of Caspase-3.
Xing
Fengxia
F
Peking University, School and Hospital of Stomatology, Beijing 100081, China.
Li
Shenglin
S
Ge
Xiyuan
X
Wang
Cunyu
C
Zeng
Huihui
H
Li
Dong
D
Dong
Ling
L
D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D053148:Caspase 3 / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008856:Microscopy, Fluorescence; D009363:Neoplasm Proteins / Q000378:metabolism*; D016566:Organoselenium Compounds / Q000494:pharmacology*; D013194:Staining and Labeling; D013880:Thioredoxin-Disulfide Reductase / Q000378:metabolism; D014062:Tongue Neoplasms / Q000139:chemically induced / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D014407:Tumor Cells, Cultured
C478160:(1,2-bis(1,2-benzisoselenazolone-3(2H)-ketone))ethane; D016588:Anticarcinogenic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D009363:Neoplasm Proteins; D016566:Organoselenium Compounds; D013880:Thioredoxin-Disulfide Reductase; D053148:Caspase 3